Literature DB >> 30446448

Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer.

Prue Cormie1, Eva M Zopf2.   

Abstract

Androgen deprivation therapy (ADT) is associated with considerable adverse side effects which compromise the health and wellbeing of many men with prostate cancer. Exercise has been identified as a therapy to help manage ADT-related treatment toxicities. This paper systematically reviews the scientific literature investigating the impact of exercise on men receiving ADT and discusses strategies to effectively implement exercise in clinical practice. The findings of this review demonstrate that exercise has therapeutic benefit for the management of ADT-related side effects. Significant positive effects following exercise were observed for aerobic fitness, muscular strength, physical function, body composition, fatigue, sexual wellbeing, mental wellbeing, social function, comorbid disease risk factors, and quality of life. Emerging evidence suggests exercise may also play a role in managing bone loss, cognitive decline, and urinary problems, and may be delivered without exacerbating bone pain. Exercise did not negatively influence ADT treatment efficacy and led to few adverse events of minor severity, rendering it a safe intervention for men receiving ADT. To maximize the therapeutic effect of exercise, men with prostate cancer should participate in moderate-to-high intensity aerobic, resistance and impact exercise which is prescribed and supervised by a qualified exercise physiologist and delivered at a convenient location in a prostate cancer specific group-based environment. The level of evidence now available supports the view that the prescription of exercise medicine should be part of routine prostate cancer care.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aerobic exercise; Resistance exercise; Urology

Mesh:

Substances:

Year:  2018        PMID: 30446448     DOI: 10.1016/j.urolonc.2018.10.008

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  4 in total

1.  Canadian Urological Association best practice report: Bone health in prostate cancer.

Authors:  Luke T Lavallée; Ryan McLarty; Christopher Tran; Rodney H Breau; Patrick Richard; Bobby Shayegan; Brita Danielson; Marie-Paul Jammal; Fred Saad
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

2.  UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.

Authors:  Andrea Kokorovic; Alan I So; Hosam Serag; Christopher French; Robert J Hamilton; Jason P Izard; Jasmir G Nayak; Frédéric Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

3.  Exercise as a supportive care strategy in men with prostate cancer receiving androgen deprivation therapy at a regional cancer centre: a survey of patients and clinicians.

Authors:  Hugh Elbourne; Wee Kheng Soo; Victoria O'Reilly; Anna Moran; Christopher B Steer
Journal:  Support Care Cancer       Date:  2021-09-14       Impact factor: 3.359

4.  Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study.

Authors:  Vanessa Sánchez-Martínez; Cristina Buigues; Rut Navarro-Martínez; Laura García-Villodre; Noura Jeghalef; María Serrano-Carrascosa; José Rubio-Briones; Omar Cauli
Journal:  Life (Basel)       Date:  2021-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.